
- /
- Supported exchanges
- / US
- / ROIV.NASDAQ
Roivant Sciences Ltd (ROIV NASDAQ) stock market data APIs
Roivant Sciences Ltd Financial Data Overview
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, the United Kingdom.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Roivant Sciences Ltd data using free add-ons & libraries
Get Roivant Sciences Ltd Fundamental Data
Roivant Sciences Ltd Fundamental data includes:
- Net Revenue: 29 053 K
- EBITDA: -1 072 609 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-29
- EPS/Forecast: -0.1633
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roivant Sciences Ltd News

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at...


Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor vid...

Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline
Earnings Call Insights: Roivant Sciences Ltd. (ROIV) Q4 2024 MANAGEMENT VIEW * CEO Matt Gline described 2025 as a critical year for Roivant, highlighting the generation of data for Batoclimab in M...

Roivant Sciences GAAP EPS of -$0.29 misses by $0.07, revenue of $7.57M
* Roivant Sciences press release [https://seekingalpha.com/pr/20119453-roivant-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2025] (NASDAQ:ROIV [https://seekingalph...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.